Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
O. Oisen, P.E. Gotzsche.
Cochrane review on screening for breast cancer with mammography.
Lancet, 358 (2001), pp. 1340-1342
[3.]
W.C. Black, D.A. Haggstrom, H.G. Welch.
All-cause mortality in randomized trials of cancer screening.
J Natl Cancer Inst, 94 (2002), pp. 167-173
[4.]
S.N. Goodman.
The mammography dilemma: a crisis for evidence- based medicine?.
Ann Intern Med, 137 (2002), pp. 363-365
[5.]
A.O. Berg, D.J. Allan, P.S. Frame, et al.
Clinical guidelines. screening for breast cancer: recommendations and rationale.
Ann Intern Med, 137 (2002), pp. 344-346
[6.]
NIH Consensus Statement.
Breast cancer screening for women ages 40-49.
NIH Consens Statement, 15 (1997), pp. 1-35
[7.]
Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer. Canadian Task Force on Preventive Health Care
[8.]
C.L. Baines.
The Canadian National Breast Screening Study: responses to controversy.
Womens Health Issues, 2 (1992), pp. 206-211
[9.]
A.B. Miller, T. To, C.J. Baines, E. Wall.
The Canadian National Breast Screening Study-l: breast cancer mortality after 11 to 16 years offollow- up. A randomized screening trial of mammography in women age 40 to 49 years.
Ann Intern Med, 137 (2002), pp. 305-312
[10.]
C.E. Ford, D. Tran, Y. Deng, V.T. Ta, W.D. Rawlinson, J.S. Lawson.
Mouse mammary tumor virus-like gene sequences in breast tumors of Australian and Vietnamese women.
Clin Cancer Res, 9 (2003), pp. 1118-1120
[11.]
A. Bazarra.
¿Son los estrógenos carcinógenos?.
Acta Gin, LIX (2002), pp. 215-216
[12.]
Bazarra-Castro MA, Bazarra A. Cáncer de mama: ¿dónde nos encontramos? [en prensa]. Acta Gin
[13.]
O. Teshigahara, F. Goshima, K. Takao, S. Kohno, L.i. Kimata, A. Nakao, et al.
Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
J Surg Oncol, 85 (2004), pp. 42-47
Copyright © 2004. Sociedad Española de Ginecología y Obstetricia